![]() ![]() ![]() An exploratory, post-hoc analysis from two Phase 3 trials of low-sodium Xywav ® (calcium, magnesium, potassium, and sodium oxybates) oral solution in narcolepsy and idiopathic hypersomnia that examined changes in blood pressure among patients previously naïve to oxybate therapy, finding that there were no clinically meaningful differences from baseline in systolic blood pressure in those treated with Xywav during the open-label study periods."Based on administrative claims data and consistent with observational studies in patients diagnosed with narcolepsy, the study found that compared to patients without idiopathic hypersomnia, patients with the condition are more likely to experience cardiovascular comorbidities, including cardiovascular disease, stroke, heart attacks and heart failure." "Findings from the CV-RHYTHM study emphasize the importance of a holistic management plan and play an important role in providing insights to clinicians on how to approach treating sleep disorders, like idiopathic hypersomnia," said Logan Schneider, MD, clinical assistant professor (affiliated) of sleep medicine, Stanford Sleep Center and Consultant Neurologist, Stanford/VA Alzheimer's Center. ![]() In addition, findings from the CV-RHYTHM study will be presented at the meeting, which found that patients with idiopathic hypersomnia experienced a significantly higher prevalence of cardiovascular comorbidities, including stroke, heart attacks and heart failure than those without this underrecognized sleep disorder. The oral presentations include findings from the real-world TENOR study, which demonstrated individualized dosing strategies for twice-nightly oxybate treatment in narcolepsy. 18, 2023 /PRNewswire/ - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17 th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil. Meeting presentations underscore the increased need for awareness around the cardiovascular and cardiometabolic comorbidities and modifiable risk factors associated with sleep disordersįourteen abstracts demonstrate Jazz Pharmaceuticals' continued leadership and commitment to expanding knowledge across rare sleep disordersĭUBLIN, Oct. Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |